Recent Quotes
My Watchlist
Indicators
Local Stocks
NewsOK Local Stocks
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY: ABBV )

106.70 USD +1.05 (+0.99%)
Official Closing Price Updated: 7:56 PM EST, Mar 5, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about AbbVie

< Previous 1 2 3 4 5 6 7 8 9
...
41 42 Next >
Allergan, an AbbVie Company, Submits New Drug Application for Investigational AGN-190584 for the Treatment of Presbyopia
- If approved, this is expected to be the first eye drop to treat presbyopia 
From PR Newswire
HUMIRA® (adalimumab) Receives FDA Approval to Treat Pediatric Patients Living with Moderately to Severely Active Ulcerative Colitis
- HUMIRA (adalimumab) is the first and only subcutaneous biologic treatment option for pediatric patients from 5 years of age with moderately to severely active ulcerative colitis[1] 
From PR Newswire
New REFRESH® DIGITAL Lubricant Eye Drops Tackle Eye Dryness Due to Everyday Screen Use
- In Today's Increasingly Digital World, Over-The-Counter REFRESH® DIGITAL Lubricant Eye Drops Bring Temporary Relief to Dry, Irritated Eyes 
From PR Newswire
Second Phase 3 Induction Study Confirms Upadacitinib (RINVOQ™) Improved Clinical, Endoscopic and Histologic Outcomes in Ulcerative Colitis Patients
- 33 percent of patients achieved the primary endpoint of clinical remission (per Adapted Mayo Score) compared to 4 percent of patients treated with placebo at week 8 (p<0.001)[1] 
From PR Newswire
AbbVie, Evolus, and Medytox Announce Resolution of Intellectual Property Litigation
AbbVie (NYSE: ABBV), Evolus (NASDAQ: EOLS) and Medytox announce settlement agreements to fully resolve all outstanding litigation, including the United States International Trade Commission (ITC) case... 
From PR Newswire
AbbVie to Present at the Cowen 41st Annual Health Care Conference
AbbVie (NYSE: ABBV) will participate in the Cowen 41st Annual Health Care Conference on Wednesday, March 3, 2021. Michael Severino, M.D., vice chairman and president, Robert A. Michael, executive vice... 
From PR Newswire
AbbVie Declares Quarterly Dividend
The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.30 per share. 
From PR Newswire
AbbVie to Present at the 10th Annual SVB Leerink Global Healthcare Conference
AbbVie (NYSE: ABBV) will participate in the 10th Annual SVB Leerink Global Healthcare Conference on Friday, February 26. Michael Severino, M.D., vice chairman and president, Robert A. Michael,... 
From PR Newswire
Psychedelics are Gaining Traction as Therapies and Medicines
FinancialBuzz.com News Commentary 
From PR Newswire
AbbVie and Caribou Biosciences Announce Collaboration and License Agreement for CAR-T Cell Products
- Collaboration leverages Caribou's next-generation CRISPR genome editing technology platform and AbbVie's antigen-specific binders 
From PR Newswire
BOTOX® (onabotulinumtoxinA) Receives FDA Approval for Pediatric Detrusor Overactivity Associated with a Neurologic Condition
-- Children living with neurogenic detrusor overactivity who are not adequately managed with anticholinergic medication now have a new treatment option prior to surgical intervention 
From PR Newswire
Aquestive Therapeutics Strengthens Board of Directors with Appointments of Julie Krop, M.D., and Marco Taglietti, M.D., and Announces Resignation of Douglas K. Bratton from Board of Directors
From GlobeNewswire News Releases
AbbVie Reports Full-Year and Fourth-Quarter 2020 Financial Results
- Reports Full-Year Diluted EPS of $2.72 on a GAAP Basis; Adjusted Diluted EPS of $10.56 
From PR Newswire
CoolSculpting® by Allergan Aesthetics Expands Body Contouring Portfolio With CoolSculpting® Elite
NEW TECHNOLOGY ALLOWS FOR THE TREATMENT OF TWO AREAS OF FAT AT ONCE AND NEW ELITE APPLICATORS DESIGNED FOR IMPROVED FIT AND COMFORT 
From PR Newswire
European Commission Approves AbbVie's RINVOQ™ (Upadacitinib) for the Treatment of Psoriatic Arthritis and Ankylosing Spondylitis
- RINVOQ (15 mg, once daily) is the first oral, once-daily, selective and reversible JAK inhibitor approved for three adult rheumatic indications in the European Union: rheumatoid arthritis, psoriatic... 
From PR Newswire
Alector Announces First Participant Dosed in Phase 2 Study Evaluating AL002 in Individuals with Early Alzheimer’s Disease
From GlobeNewswire News Releases
Biotech Is Fueling An All-New Cannabis Boom
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Biotech Is Fueling An All-New Cannabis Boom
- FN Media Group Presents Safehaven.com Market Commentary 
From PR Newswire
Allergan Aesthetics and Allergan, an AbbVie Company, to Present 16 Neurotoxin Research Abstracts Across Multiple Therapeutic and Cosmetic Indications at the TOXINS 2021 Virtual Conference
- BOTOX® (onabotulinumtoxinA) and BOTOX Cosmetic® clinical data across multiple therapeutic and aesthetic indications 
From PR Newswire
Harpoon Therapeutics Granted Orphan Drug Designation from FDA for HPN217 for Treatment of Multiple Myeloma
From GlobeNewswire News Releases
Allergan Aesthetics Enters Into Option to Acquire Cypris Medical
-- Agreement Includes Development of Xact Device, a Minimally-Invasive Alternative Option for Performing Face and Neck Lifts -- 
From PR Newswire
Researchers Seek to Better Understand Psychedelics' Role in New Therapies
FinancialBuzz.com News Commentary 
From PR Newswire
AbbVie to Host Fourth-Quarter and Full-Year 2020 Earnings Conference Call
AbbVie (NYSE: ABBV) will announce its fourth-quarter and full-year 2020 financial results on Wednesday, February 3, 2021, before the market opens. AbbVie will host a live webcast of the earnings... 
From PR Newswire
Dragonfly Therapeutics Announces AbbVie Opt-In of TriNKET™ Immunotherapy Drug Candidate
Dragonfly Therapeutics ("Dragonfly"), a biotechnology company developing novel immunotherapies that harness the innate immune system to treat disease, today announced that AbbVie (NYSE: ABBV), has... 
From PR Newswire
Risankizumab (SKYRIZI®) Demonstrates Significant Improvements in Clinical Remission and Endoscopic Response in Two Phase 3 Induction Studies in Patients with Crohn's Disease
- A significantly greater proportion of patients with Crohn's disease treated with either dose of risankizumab (600 mg or 1200 mg) achieved both primary endpoints, demonstrating statistically... 
From PR Newswire
AbbVie to Present at the 39th Annual J.P. Morgan Healthcare Conference
AbbVie (NYSE: ABBV) will participate in the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021. Members of AbbVie's executive leadership team will present virtually at 3:30 p.m.... 
From PR Newswire
Risankizumab (SKYRIZI®) Phase 3 Results Demonstrate Improvements in Disease Activity Across Joint and Skin Symptoms Among Psoriatic Arthritis Patients
- In KEEPsAKE-1 and KEEPsAKE-2, 57 and 51 percent of patients receiving risankizumab achieved the primary endpoint of ACR20 response at week 24, respectively, versus 34 and 27 percent receiving placebo... 
From PR Newswire
IMBRUVICA® (ibrutinib) U.S. Prescribing Information Updated to Include Long-Term Data for Waldenström's Macroglobulinemia (WM)
- Updates are based on more than five years of Phase 3 iNNOVATE final analysis data, which demonstrated IMBRUVICA plus rituximab significantly prolonged progression-free survival (PFS) versus rituximab... 
From PR Newswire
CHMP Recommends the Approvals of RINVOQ™ (Upadacitinib) for the Treatment of Adults with Active Psoriatic Arthritis and Ankylosing Spondylitis
- Across pivotal clinical trial programs, RINVOQ (15 mg, once daily) demonstrated efficacy across multiple measures of disease activity in psoriatic arthritis (PsA) and ankylosing spondylitis (AS),... 
From PR Newswire
RINVOQ™ (upadacitinib) Achieved Superiority Versus DUPIXENT® (dupilumab) For Primary and All Ranked Secondary Endpoints in Phase 3b Head-to-Head Study in Adults with Atopic Dermatitis
- 71 percent of patients treated with upadacitinib achieved the primary endpoint of EASI 75 compared to 61 percent of patients treated with dupilumab at week 16 (p=0.006)[1] 
From PR Newswire
< Previous 1 2 3 4 5 6 7 8 9
...
41 42 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.